Anika Therapeutics was granted regulatory approval in India for MONOVISC® single injection viscosupplement to treat osteoarthritis pain in all human synovial joints. The product will be marketed in the region by Modi-Mundipharma under terms of a multi-year exclusive agreement.
Global distribution of MONOVISC is Anika’s primary international orthobiologics revenue driver. Presently available in Canada, Europe and the U.S., MONOVISC will be expanded into Australia, India, New Zealand and other ex-U.S. markets over six to nine months.
Anika Therapeutics was granted regulatory approval in India for MONOVISC® single injection viscosupplement to treat osteoarthritis pain in all human synovial joints. The product will be marketed in the region by Modi-Mundipharma under terms of a multi-year exclusive agreement.
Global distribution of MONOVISC is Anika's primary international...
Anika Therapeutics was granted regulatory approval in India for MONOVISC® single injection viscosupplement to treat osteoarthritis pain in all human synovial joints. The product will be marketed in the region by Modi-Mundipharma under terms of a multi-year exclusive agreement.
Global distribution of MONOVISC is Anika’s primary international orthobiologics revenue driver. Presently available in Canada, Europe and the U.S., MONOVISC will be expanded into Australia, India, New Zealand and other ex-U.S. markets over six to nine months.
Copy to clipboard 
